Eye infection breakthrough: new study tests best antiviral approach
NCT ID NCT03586284
First seen Feb 16, 2026 · Last updated May 06, 2026 · Updated 12 times
Summary
This study compared oral valganciclovir, topical ganciclovir 2%, and placebo for treating CMV anterior uveitis, a viral eye infection that can cause pain, glaucoma, and vision loss. The trial enrolled 51 adults with confirmed CMV in the eye. The goal was to see which treatment better reduced the virus and controlled inflammation, helping guide future care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS ANTERIOR UVEITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiang Mai University
Chiang Mai, Thailand
-
Chulalongkorn University
Bangkok, Thailand
-
Khon Kaen University
Khon Kaen, Thailand
-
Proctor Foundation, UCSF
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.